论文部分内容阅读
作者对343名健康成人和166例血液透析病人接种高度纯化的、福尔马林灭活的ad亚型乙型肝炎疫苗,进行了免疫原性研究。健康成人组中,男151人,女192人,年龄分别为31±8岁和29±9岁,均为医务人员。血液透析病人组中,男94人,女72人,年龄分别为50±13岁和49±14岁。免疫使用的疫苗,Ⅱ/310781批每支效价13,800国际单位(IU),50%阳性反应值1:183;I/B070881批每支效价11,300IU,50%阳性反应值1:64。I/B070881批疫苗有40、20和8μg三种剂量,接种程序为0-1-6月。Ⅱ/310781
The authors conducted immunogenicity studies of 343 healthy adults and 166 hemodialysis patients with highly purified, formalin-inactivated ad subtype hepatitis B vaccine. In the healthy adult group, there were 151 males and 192 females, aged 31 ± 8 years and 29 ± 9 years, respectively, and all of them were medical staff. Hemodialysis patient group, 94 males and 72 females, aged 50 ± 13 years and 49 ± 14 years. Vaccine used for immunization, II / 310781 lot Each titer 13,800 IU, 50% positive response value 1: 183; I / B070881 lot each titer 11,300 IU, 50% positive response value 1:64. The I / B070881 vaccine was given in three doses of 40, 20 and 8 μg, and the inoculation procedure was 0-1-6 months. II / 310781